Therapy for hyperexcitability disorders
The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.
1. A method for alleviating and/or treating a myotonia in a subject in need thereof, comprising administering to the subject lacosamide or a pharmaceutically acceptable salt thereof.
2. The method of claim 1 , wherein the myotonia is a disease associated with dysfunction of a voltage-gated ion channel.
3. The method of claim 1 , wherein the myotonia is associated with a mutation at SCN4A or CLCN1.
4. The method of claim 3 , wherein the myotonia associated with a mutation at SCN4A is selected from the group consisting of paramyotonia congenita and potassium aggravated myotonia.
5. The method of claim 4 , wherein the potassium aggravated myotonia is myotonia fluctuans.
6. The method of claim 4 , wherein the potassium aggravated myotonia is myotonia permanens.
7. The method of claim 4 , wherein the potassium aggravated myotonia is acetazolamide responsive myotonia.
8. The method of claim 3 , wherein the myotonia associated with a mutation at CLCN1 is selected from the group consisting of myotonia congenital, generalized and myotonia levior.
9. The method of claim 8 , wherein the myotonia congenita is Thomsen myotonia.
10. The method of claim 8 , wherein the myotonia congenita is Becker myotonia.
11. The method of claim 1 , wherein the myotonia is selected from the group consisting of paramyotonia congenita and potassium aggravated myotonia.
12. The method of claim 11 , wherein the potassium aggravated myotonia is myotonia fluctuans.
13. The method of claim 11 , wherein the potassium aggravated myotonia is myotonia permanens.
14. The method of claim 11 , wherein the potassium aggravated myotonia is acetazolamide responsive myotonia.
15. The method of claim 1 , wherein the myotonia is selected from the group consisting of myotonia congenital and myotonia levior.
16. The method of claim 15 , wherein the myotonia congenita is Thomsen myotonia.
17. The method of claim 15 , wherein the myotonia congenita is Becker myotonia.
18. The method of claim 1 , wherein lacosamide or a pharmaceutically acceptable salt thereof is administered in a dosage amount of 50 mg/day to 1000 mg/day.
19. The method of claim 1 , wherein lacosamide or a pharmaceutically acceptable salt thereof is administered in a dosage amount of 200 mg/day to 600 mg/day.
20. The method of claim 1 , further comprising administering to the subject at least one further active agent for alleviation and/or treatment of a myotonia.